These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22391507)

  • 21. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis.
    Jasperse B; Minneboo A; de Groot V; Kalkers NF; van Helden PE; Uitdehaag BM; Barkhof F; Polman CH
    Arch Neurol; 2007 Feb; 64(2):190-4. PubMed ID: 17296834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
    J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.
    Eisele P; Szabo K; Ebert A; Platten M; Gass A
    J Neuroimaging; 2019 Mar; 29(2):190-192. PubMed ID: 30485572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis.
    Fritz DA; Dwyer MG; Bagnato F; Watts KL; Bratina A; Zorzon M; Durastanti V; Locatelli L; Millefiorini E; Zivadinov R
    Neurol Res; 2006 Apr; 28(3):275-9. PubMed ID: 16687053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.
    van den Elskamp IJ; Boden B; Dattola V; Knol DL; Filippi M; Kappos L; Fazekas F; Wagner K; Pohl C; Sandbrink R; Polman CH; Uitdehaag BM; Barkhof F
    Neuroradiology; 2010 Oct; 52(10):875-81. PubMed ID: 20049424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
    Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
    Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
    Vennegoor A; Rispens T; Strijbis EM; Seewann A; Uitdehaag BM; Balk LJ; Barkhof F; Polman CH; Wolbink G; Killestein J
    Mult Scler; 2013 Apr; 19(5):593-600. PubMed ID: 22992450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans.
    Cover KS; van Schijndel RA; van Dijk BW; Redolfi A; Knol DL; Frisoni GB; Barkhof F; Vrenken H; ;
    Psychiatry Res; 2011 Sep; 193(3):182-90. PubMed ID: 21764565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab use in pediatric multiple sclerosis.
    Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
    Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis.
    Maghzi AH; Revirajan N; Julian LJ; Spain R; Mowry EM; Liu S; Jin C; Green AJ; McCulloch CE; Pelletier D; Waubant E
    Mult Scler Relat Disord; 2014 Nov; 3(6):720-7. PubMed ID: 25891551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis.
    Sbardella E; Tomassini V; Stromillo ML; Filippini N; Battaglini M; Ruggieri S; Ausili Cefaro L; Raz E; Gasperini C; Sormani MP; Pantano P; Pozzilli C; De Stefano N
    Mult Scler; 2011 Dec; 17(12):1432-40. PubMed ID: 21729978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentrations of immunoglobulin free light chains in cerebrospinal fluid predict increased level of brain atrophy in multiple sclerosis.
    Nazarov V; Makshakov G; Kalinin I; Lapin S; Surkova E; Mikhailova L; Gilburd B; Skoromets A; Evdoshenko E
    Immunol Res; 2018 Dec; 66(6):761-767. PubMed ID: 30635824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: a voxel-based morphometry study.
    Duan Y; Liu Y; Liang P; Jia X; Yu C; Qin W; Sun H; Liao Z; Ye J; Li K
    Eur J Radiol; 2012 Feb; 81(2):e110-4. PubMed ID: 21316170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of natalizumab in children with multiple sclerosis.
    Ghezzi A; Pozzilli C; Grimaldi LM; Brescia Morra V; Bortolon F; Capra R; Filippi M; Moiola L; Rocca MA; Rottoli M; Sarchielli P; Zaffaroni M; Comi G
    Neurology; 2010 Sep; 75(10):912-7. PubMed ID: 20820002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natalizumab dosage suspension: are we helping or hurting?
    West TW; Cree BA
    Ann Neurol; 2010 Sep; 68(3):395-9. PubMed ID: 20818793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L; Parigi A; Barilaro A; Repice AM; Pellicanò G; Konze A; Siracusa G; Taiuti R; Amaducci L
    Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.